US scrutiny of China clinical trials threatens biotech edge

US lawmakers and FDA officials are raising concerns about American pharma reliance on early-stage clinical trials in China, citing opacity and national security. Analysts warn potential US restrictions could erode China's cost and speed advantage in biopharmaceutical development. The outcome is uncertain, but any regulatory shift would reshape global drug development supply chains.